Advances in oncolytic herpes simplex virus and adenovirus therapy for recurrent glioma

被引：13
作者：
Hu, Mingming [1 ,2 ]
Liao, Xuliang [1 ,2 ]
Tao, Yi [1 ,2 ]
Chen, Yaohui [1 ,3 ]
机构：
[1] Sichuan Univ, West China Hosp, Inst Thorac Oncol, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, Frontiers Sci Ctr Dis Related Mol Network, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Dept Thorac Surg, Chengdu, Peoples R China
来源：
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词：
oncolytic viruses; cancer therapy; recurrent gliomas; oncolytic herpes simplex virus; adenovirus therapy; RETROVIRAL REPLICATING VECTORS; HUMAN-MALIGNANT GLIOMA; TYPE-1 MUTANT G207; HIGH-GRADE GLIOMA; ZIKA VIRUS; PROTEIN-SYNTHESIS; CELL-DEATH; P53; STATUS; ADJUVANT TEMOZOLOMIDE; SAFETY EVALUATION;
D O I：
10.3389/fimmu.2023.1285113
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Recurrent glioma treatment is challenging due to molecular heterogeneity and treatment resistance commonly observed in these tumors. Researchers are actively pursuing new therapeutic strategies. Oncolytic viruses have emerged as a promising option. Oncolytic viruses selectively replicate within tumor cells, destroying them and stimulating the immune system for an enhanced anticancer response. Among Oncolytic viruses investigated for recurrent gliomas, oncolytic herpes simplex virus and oncolytic adenovirus show notable potential. Genetic modifications play a crucial role in optimizing their therapeutic efficacy. Different generations of replicative conditioned oncolytic human adenovirus and oncolytic HSV have been developed, incorporating specific modifications to enhance tumor selectivity, replication efficiency, and immune activation. This review article summarizes these genetic modifications, offering insights into the underlying mechanisms of Oncolytic viruses' therapy. It also aims to identify strategies for further enhancing the therapeutic benefits of Oncolytic viruses. However, it is important to acknowledge that additional research and clinical trials are necessary to establish the safety, efficacy, and optimal utilization of Oncolytic viruses in treating recurrent glioblastoma.
引用
收藏
页数：17
相关论文
共 50 条
[31]   Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta [J].
Jiani Wang ;
Lihua Xu ;
Weigen Zeng ;
Pan Hu ;
Musheng Zeng ;
Samuel D Rabkin ;
Renbin Liu .
Cancer Cell International, 14
[32]   Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells [J].
Passer, B. J. ;
Castelo-Branco, P. ;
Buhrman, J. S. ;
Varghese, S. ;
Rabkin, S. D. ;
Martuza, R. L. .
CANCER GENE THERAPY, 2009, 16 (07) :551-560
[33]   Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta [J].
Wang, Jiani ;
Xu, Lihua ;
Zeng, Weigen ;
Hu, Pan ;
Zeng, Musheng ;
Rabkin, Samuel D. ;
Liu, Renbin .
CANCER CELL INTERNATIONAL, 2014, 14
[34]   ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties [J].
Liu, BL ;
Robinson, M ;
Han, ZQ ;
Branston, RH ;
English, C ;
Reay, P ;
McGrath, Y ;
Thomas, SK ;
Thornton, M ;
Bullock, P ;
Love, CA ;
Coffin, RS .
GENE THERAPY, 2003, 10 (04) :292-303
[35]   Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children [J].
Cripe, Timothy P. ;
Chen, Chun-Yu ;
Denton, Nicholas L. ;
Haworth, Kellie B. ;
Hutzen, Brian ;
Leddon, Jennifer L. ;
Streby, Keri A. ;
Wang, Pin-Yi ;
Markert, James M. ;
Waters, Alicia M. ;
Gillespie, George Yancey ;
Beierle, Elizabeth A. ;
Friedman, Gregory K. .
MOLECULAR THERAPY-ONCOLYTICS, 2015, 2 :15015
[36]   Hypoxia enhances the replication of oncolytic herpes simplex virus in p53- breast cancer cells [J].
Fasullo, Michael ;
Burch, April D. ;
Britton, Alicia .
CELL CYCLE, 2009, 8 (14) :2194-2197
[37]   The In Vitro Replication, Spread, and Oncolytic Potential of Finnish Circulating Strains of Herpes Simplex Virus Type 1 [J].
Kalke, Kiira ;
Orpana, Julius ;
Lasanen, Tuomas ;
Esparta, Olaya ;
Lund, Liisa M. ;
Frejborg, Fanny ;
Vuorinen, Tytti ;
Paavilainen, Henrik ;
Hukkanen, Veijo .
VIRUSES-BASEL, 2022, 14 (06)
[38]   Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer [J].
Crespo-Rodriguez, Eva ;
Bergerhoff, Katharina ;
Bozhanova, Galabina ;
Foo, Shane ;
Patin, Emmanuel C. ;
Whittock, Harriet ;
Buus, Richard ;
Haider, Syed ;
Muirhead, Gareth ;
Thway, Khin ;
Newbold, Kate ;
Coffin, Robert S. ;
Vile, Richard G. ;
Kim, Dae ;
McLaughlin, Martin ;
Melcher, Alan A. ;
Harrington, Kevin J. ;
Pedersen, Malin .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
[39]   Oncolytic herpes simplex virus kills stem-like tumor-initiating colon cancer cells [J].
Warner, Susanne G. ;
Haddad, Dana ;
Au, Joyce ;
Carson, Joshua S. ;
O'Leary, Michael P. ;
Lewis, Christina ;
Monette, Sebastien ;
Fong, Yuman .
MOLECULAR THERAPY-ONCOLYTICS, 2016, 3 :16013
[40]   Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1 [J].
Thomas, Suzanne ;
Kuncheria, Linta ;
Roulstone, Victoria ;
Kyula, Joan N. ;
Mansfield, David ;
Bommareddy, Praveen K. ;
Smith, Henry ;
Kaufman, Howard L. ;
Harrington, Kevin J. ;
Coffin, Robert S. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01)
12345